Ticagrelor
FDA-approved product (tablet, oral), marketed as Brilinta, Ticagrelor.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute coronary syndrome
- Acute myocardial infarction
- Coronary artery disease
- Myocardial infarction
- Peripheral vascular disease
- Recurrent thrombophlebitis
- Stroke
- Thrombotic disease
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- FDA pharmacologic class
- P2Y12 Platelet Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ticagrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Canadian Ticagrelor Survey
NCT01757483 · start 2012-11
Registered record
- Registry ID
- NCT01757483
- Conditions
- Acute Coronary Syndrome
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2014-12
- Enrolment
- 244
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionNot recordedPhaseNot recordedRegistry statusCompletedDifferential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
NCT01642966 · start 2012-09
Registered record
- Registry ID
- NCT01642966
- Conditions
- Acute Coronary Syndrome
- Interventions
- Prasugrel; Ticagrelor
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2012-09
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionPrasugrel; TicagrelorPhasePhase 4Registry statusCompletedPROMUS Element Plus US Post-Approval Study
NCT01589978 · start 2012-05
Registered record
- Registry ID
- NCT01589978
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonist
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-05
- Completion
- 2018-06
- Enrolment
- 2,681
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionPROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonistPhasePhase 4Registry statusCompletedPharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
NCT01587651 · start 2012-03
Registered record
- Registry ID
- NCT01587651
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2013-02
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionPrasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance DosePhasePhase 4Registry statusCompletedCost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
NCT01761786 · start 2011-06
Registered record
- Registry ID
- NCT01761786
- Conditions
- Myocardial Infarction; STEMI
- Interventions
- CYP2C19 genotyping
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2019-04-04
- Enrolment
- 2,700
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Infarction; STEMIInterventionCYP2C19 genotypingPhasePhase 4Registry statusCompleted